Blood biomarker to predict future Alzheimer's disease

Written By : Isra Zaman

Medically Reviewed By : Dr. Kamal Kant Kohli

Published On 2023-05-30 03:30 GMT | Update On 2023-05-30 08:47 GMT

Why do some people develop Alzheimer's disease while others don't? And, even more puzzlingly, why do many individuals whose brains are chock-full of 1 toxic amyloid aggregates-a telltale sign of Alzheimer’s brain pathology-never go on to develop Alzheimer’s-associated dementias?

2University of Pittsburgh School of Medicine researchers appear to have found the answer. Star-shaped brain cells called astrocytes are key to swaying the pendulum in Alzheimer’s disease progression, shows new game-changing research published today in Nature Medicine.

By testing the blood of more than 1,000 cognitively unimpaired elderly people with and without amyloid pathology, the Pitt-led research team found that only those who had a combination of amyloid burden and blood markers of abnormal astrocyte activation, or reactivity, would progress to 3symptomatic Alzheimer’s in the future, a critical discovery for drug development aimed at halting progression.

Scientists tested blood samples from participants in three independent studies of cognitively unimpaired elderly people for biomarkers of astrocyte reactivity-glial fibrillary acidic protein, or GFAP-along with the presence of pathological tau. The study showed that only those who were positive for both amyloid and astrocyte reactivity showed evidence of progressively developing tau pathology, indicating predisposition to 4clinical symptoms of Alzheimer’s disease.

Reference:

Astrocyte reactivity influences amyloid-β effects on tau pathology in preclinical Alzheimer’s disease,Nature Medicine, DOI 10.1038/s41591-023-02380-x

Full View

Article Source : Nature Medicine

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Isra Zaman

Isra Zaman is a Life Science graduate from Daulat Ram College, Delhi University, and a postgraduate in Biotechnology from Amity University. She has a flair for writing, and her roles at Medicaldialogues include that of a Sr. content writer and a medical correspondent. Her news pieces cover recent discoveries and updates from the health and medicine sector. She can be reached at editorial@medicaldialogues.in.

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Blood biomarker to predict future Alzheimer's disease

Similar News

Can Blood Tests Replace Brain Scans for Alzheimer's? New Study Says Yes

Artificial Sweeteners Could Speed Up Brain Aging by 1.6 Years: Study Finds

Head Injuries May Raise Brain Cancer Risk: Major Studies Reveal

Tiny Gold Nanoparticles Show Promise For Early Parkinson's Disease Detection: Study Suggests

New 2025 Hypertension Guidelines Released with Stronger Focus on Brain Health and Early Intervention

Women with Down Syndrome More Vulnerable to Alzheimer's Than Men: Study Finds

Multiple Sclerosis May Begin 15 Years Earlier with Subtle Symptoms: Study Suggests

Can This Common Diabetes Drug Prevent Stroke? Emerging Data Suggests Strong Link